Effect of primary percutaneous coronary intervention combined with eptifibatide on patients with STsegment elevation myocardial infarction

Wang Huimin; Liu Chao; Chu Yushun; Zhao Yanye

doi:10.3969/j.issn.1674-4055.2018.12.06

Abstract：Objective To investigate the efficacy and safety of primary percutaneous coronary intervention combined with eptifibatide on patients with ST-segment elevation myocardial infarction (STEMI).Methods 102STEMI patients in Affiliated Hospital of Logistics College of the Chinese people's Armed Police Force from October2016 to October 2017 were selected and randomly divided into the study group and the control group, with 51patients in each group.The control group was treated with PCI, and the study group was treated with eptifibatide on the basis of the control group.The postoperative TIMI blood flow grading, corrected TIMI frame count (cTFC), ST segment fallback, platelet aggregation rate, and bleeding events were compared between the two groups.Results Compared with the control group, there were more TIMI grade 3 cases in the study group, and the difference was statistically significant (P＜0.05).The CTFC value of the study group (18.37±2.40) was smaller than that of the control group (20.93±2.65), and the difference was statistically significant (P＜0.05).After treatment, the ST segment was better than the control group, and the difference was statistically significant (P＜0.05).Platelet aggregation rate in the control group did not change significantly before, after, and after withdrawal.The platelet aggregation rate of the study group was significantly lower than that of the control group 2 h after the operation and the drug was stopped, and the difference was statistically significant (P＜0.05).There was no significant difference in the incidence of major adverse cardiovascular events between the study group and the control group at 30 days after surgery (P＞0.05).Conclusion Percutaneous coronary intervention combined with eptifibatide has a good therapeutic effect and safety.